SCYNEXIS, Inc. Stock Split Ratio
SCYNEXIS, Inc. (SCYX) had Stock Split Ratio of 12.50% as of 2026-05-28, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-08-10
- 2026-05-28: Stockholders' Equity Note, Stock Split, Conversion Ratio 12.50%.
- 2020-07-16: Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 10.00%.
- 2014-04-25: Stockholders' Equity Note, Stock Split, Conversion Ratio 19.60%.
- 2014-03-17: Stockholders' Equity Note, Stock Split, Conversion Ratio 25.00%; Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month 25.00%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio 0 month |
|---|---|---|
| 2026-05-28 | 12.50% 10-Q · filed 2026-08-10 | |
| 2020-07-16 | 10.00% 10-Q · filed 2021-11-10 | |
| 2014-04-25 | 19.60% 8-K · filed 2015-10-30 | |
| 2014-03-17 | 25.00% 10-K · filed 2016-03-07 | 25.00% 10-Q/A · filed 2014-07-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |